Discover expanded psychiatry coverage with new podcasts, interactive digital issues, and event reporting—we are your always-on media hub delivering fresh insights year-round.
|Videos|October 29, 2020
The Pervasive Fear of Going to Work
Author(s)David “Daven” E. Morrison, MD
Keeping up your energy at work is difficult with the stressors of COVID-19, social unrest, and the upcoming election. As a mental health professional, how can you help alleviate this fear?
Advertisement
Dr Daven Morrison talks about the myriad of issues surrounding the current complex workplace.
Dr Morrison is Assistant Clinical Professor of Psychiatry at Chicago Medical School.
Advertisement
Related to this article
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Miss Golden Corner 2026 discusses the South Carolina campus naloxone law she helped start and her push to reduce addiction stigma in rural communities.
Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
BCG vaccination curbs tau tangles in mice by boosting microglial cleanup, fueling hopes for human trials to reduce dementia risk.
GLP-1 weight-loss drugs may worsen eating disorders or mask symptoms; experts urge careful screening, specialist referral, and monitoring before, during, and after use.
Sabirnetug phase 2 Alzheimer trial misses cognitive endpoint despite lowering amyloid, prompting Acumen to halt development and open-label extension plans.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Brain Trust: Bessel van der Kolk, MD, on Complex PTSD, Attachment, and the Limits of Pharmacotherapy
3
Podcast: Campus Naloxone Access and Destigmatizing Substance Use Disorders
4
Artificial Intelligence in Psychiatric Clinical Trials: Opportunities and Limitations
5